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ttp://dx.doi.org/10.1016/j.ajpath.2013.04.025We have recently shown acetylation of tau at lysine residue 280 (AC-K280) to be a disease-speciﬁc
modiﬁcation in Alzheimer disease (AD), corticobasal degeneration, and progressive supranuclear palsy,
likely representing a major regulatory tau modiﬁcation. Herein, we extend our observations using IHC
with a polyclonal antibody speciﬁc for AC-K280. Thirty brain regions were examined in argyrophilic grain
disease (AGD; nZ 5), tangle-predominant senile dementia (TPSD; nZ 5), Pick disease (nZ 4), familial
AD (FAD; nZ 2; PSEN1 p.G206A and p.S170P), and frontotemporal dementia with parkinsonism linked to
chromosome-17 (FTDP-17; nZ 2; MAPT p.P301L and IVS10þ 16). All AGD, TPSD, FAD, and FTDP-17 cases
had signiﬁcant AC-K280 reactivity that was similar in severity and distribution to phosphorylated tau. AC-
K280 robustly labeled grain pathological characteristics in AGD and was predominantly associated with
thioﬂavin-Sepositive neuroﬁbrillary tangles and less reactive in neuropil threads and extracellular
tangles in TPSD and FAD. Thioﬂavin-Senegative neuronal and glial inclusions of patients with FTDP-17
were robustly AC-K280 reactive. A low degree of AC-K280 was found in a subset of 4-repeat tau-
containing lesions in Pick disease. AC-K280 is a prominent feature of both neuronal and glial tau
aggregations in tauopathies of various etiologies. The close association of AC-K280 with amyloid and pre-
amyloid conformations of tau suggests a potential role in tangle maturation and, thus, could serve as
a useful biomarker or therapeutic target in a variety of tauopathies. (Am J Pathol 2013, 183: 344e351;
http://dx.doi.org/10.1016/j.ajpath.2013.04.025)Supported by NIH grants P30 AG10124, AG17586, and T32-AG000255
(D.J.I. received the last grant only).
Disclosures: S.A.E. has board membership at Cowan Group, Eli Lilly, and
BMS, provides consulting services for a Philadelphia district attorney’s ofﬁce
andBonnerKiernanTrebach&CociataLLP, and receivedpayments for lectures
at Harvard University, Rush University Medical Center, Trinitas Regional
Medical Center, and University of Puerto Rico. V.M.-Y.L. and J.Q.T. report
single consulting services to Pﬁzer, J&J,MetLife, andBMS, and receive royalty
payments through University of Pennsylvania licenses.Tauopathies are a heterogeneous group of neurodegenerative
diseases characterized by abnormal conformations of tau
proteins incorporated into inclusions and resulting in neu-
ronal loss and gliosis. Pathogenic mutations in theMAPT tau
gene causing frontotemporal dementia with parkinsonism
linked to chromosome-17 (FTDP-17),1 with characteristic
tau lesions at autopsy, provide compelling evidence of
a central role of tau aggregation in disease pathogenesis.
Tau is subject to multiple post-translational modiﬁcations
that, in disease states, may become dysregulated and contribute
to pathological aggregation.2 Previously, our group3 and
others4 have found that tau is modiﬁed by acetylation on
lysine residues within the microtubule (MT)ebinding domain
(MTBD). Two main categories of tau isoforms exist, based on
alternative splicing of exon 10 for inclusion or exclusion of the
secondMTBDfor a total of 3 (3R) or 4 (4R)MTBDrepeats.Westigative Pathology.
.found acetylation of lysine 280 (AC-K280) in the second
MTBD in 4R tau to be disease speciﬁc, resulting in both
decreased microtubule binding and increased ﬁbrillization
in vitro.3 Furthermore, AC-K280 is a prominent marker of
pathological characteristics in Alzheimer disease (AD), corti-
cobasal degeneration (CBD), and progressive supranuclear
palsy (PSP).5 Herein, we further examine the AC-K280
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characterized by insoluble 4R tau-predominant ﬁlaments,
including argyrophilic grain disease (AGD), tangle-
predominant senile dementia (TPSD), FTDP-17, and familial
AD (FAD) cases caused by presenillin-1 (PSEN1) mutations.
We also examined cases of the predominantly 3R tauopathy,
Pick disease (PiD), because heterogeneity exists in the tau iso-
form proﬁle in insoluble deposits of tau in the brains of patients
with PiD.6e8
Materials and Methods
Patients
Patientswere seen at theUniversity of Pennsylvania Perelman
School of Medicine (Philadelphia) Alzheimer’s Disease
Center or Frontotemporal DegenerationCenter, and autopsies
were performed at the Center for Neurodegenerative Disease
Research. Autopsies were performed with informed consent,
and all procedures were done in accordance with the local
Institutional Review Board guidelines. Patient demographics
were obtained from our integrated neurodegenerative disease
database9 (Supplemental Table S1). Neuropathological as-
sessment and diagnosis were performed as reported previ-
ously10 using established criteria.11,12 Tau and amyloid b
pathological characteristics were staged according to Braak
and Braak13 and the Consortium to Establish a Registry for
Alzheimer’s Disease14 criteria, respectively. AGD cases were
staged according to Ferrer et al.15 Thirty areas were sampled
and analyzed for ﬁve cases each of AGD and TPSD, four
cases of PiD, and several hereditary FAD and FTDP-17 cases
[n Z 1: PSEN1 p.G206A,16 PSEN1 p.S170P, MAPT
p.P301L,1 and MAPT IVS10 þ 16 (c.915 þ 16C>T)1]. We
also examined available regions in two nonneurodegenerative
control cases (Braak stage 0) (Supplemental Table S1).
The PSEN1 p.S170P mutation has not been previously
reported, but it is likely pathogenic in view of the extremely
young age of disease onset (27 years) in this patient and the
family history of AD among the kindred of this patient
(Supplemental Figure S1), as well as a similar reported
pathogenic mutation at this residue (p.S170F).17
IHC Data
Fresh tissue was sampled at autopsy and ﬁxed in 70% ethanol/
150 mmol sodium chloride, embedded in parafﬁn, and cut into
sections (6 mm thick). Immunohistochemistry (IHC) was per-
formed, as previously described,5 using a rabbit-generated
polyclonal antibody speciﬁc for tau modiﬁed with an acetyl
group at the 280 lysine (K) residue3 (AC-K280; 1:250 to
1:1000 dilution) and an avidin-biotin complex detection
system (VECTASTAIN ABC kit; Vector Laboratories, Bur-
lingame, CA) with 3,30-diaminobenzidine as the chromogen.
AC-K280 speciﬁcity for themodiﬁed lysine residue has been
described in detail.3 Mouse monoclonal antibodies (mAbs)
speciﬁc for other tau epitopes were used herein, and theyThe American Journal of Pathology - ajp.amjpathol.orginclude phosphorylated tau [PHF-118; 1:500 to 1:1000;
courtesy of Dr. Peter Davies (Albert Einstein College of
Medicine, Department of Pathology, Bronx, NY)] and 3R
(RD319; 1:2500 to 1:5000; Millipore, Billerica, MA) and 4R
(RD419; 1:5000 to 1:10,000; Millipore) tau isoforms.
Antigen retrieval was performed by using 88% formic acid
for AC-K280 and RD3 or boiling with a citric acid
unmasking solution (Vector Laboratories) for RD4.
Double-label immunoﬂuorescence experiments were per-
formed as described5 using AC-K280 and tau-speciﬁc mAbs
or thioﬂavin-S (ThS) amyloid dye staining for ﬁbrillar
inclusions and Alexa Fluor 488 and 594 species-speciﬁc
conjugated secondary antibodies (Invitrogen, Grand Island,
NY). To conﬁrm the 4R tau predominance in AGD grains
and presence of 4R tau in PiD cases, serial sections and
double-label experiments with AC-K280 and RD3/RD4were
performed on hippocampal sections of AGD (n Z 4) and
three areas of high AC-K280 reactivity in one PiD case
(anterior cingulate gyrus, motor cortex, and temporal cortex).
ThS and AC-K280 double labeling was also examined in
these regions for AGD and PiD and, in addition, in TPSD
hippocampus (n Z 4), FAD hippocampus or frontal cortex
(nZ 2), and FTDP-17 hippocampus or temporal neocortex
(n Z 2). Digital images of immunoﬂuorescence were ob-
tained with an Olympus BX 51 microscope equipped with
a bright-ﬁeld and ﬂuorescence light source with a DP-71
digital camera (Olympus, Center Valley, PA) and DP
manager software version 3.1.1.208 (Olympus) and overlaid
into a merge channel using Adobe Photoshop version 9.0.2
(Adobe Systems, San Jose, CA).Genetic Analysis
For the hereditary cases in this study, DNA was extracted
from peripheral blood samples or brain tissue using the
manufacturer’s protocol (Flexigene; Qiagen, Valencia,
CA) or the Quick-Gene DNA whole blood kit (Autogen,
Holliston, MA). DNA sequence analysis of the entire
coding region of PSEN1 and targeted regions of MAPT
known to harbor pathogenic mutations (exons 1 and 9 to
13) was performed as previously described.16,20 Data were
analyzed for identiﬁcation of mutations with Mutation
Surveyor software version 4.0.7 (Soft Genetics, State
College, PA).Microscopic and Statistical Analysis
Regional distribution and severity of AC-K280 were
compared with PHF-1 across 30 representative central
nervous system regions and graded on a semiquantitative
scale, as previously described5 (0, none or rare patholog-
ical feature; 1, weak; 2, moderate; and 3, strong). Median
semiquantitative scores for grouped data were calculated
for each region per disease group using SPSS, version 19.0
(SPSS Inc., Chicago, IL).345
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Regional Distribution
Detailed neuropathological assessment in 30 representative
cortical and subcortical regions of the CNS revealed AC-
K280 in a similar distribution and severity to the well-
described PHF-1 phosphorylated-epitope of tau (Ser396/
404)18 in AGD, TPSD, FAD, and FTDP-17 cases (Figure 1
and Supplemental Tables S2, S3, and S4). AC-K280
immunoreactivity was not found in areas negative for
PHF-1, and, similarly, in regions with weak or rare PHF-1
pathological features, there was often no detectable AC-
K280. This was also true in control cases, in which AC-
K280 was limited to rare (one to three tangles) in the
cornu ammonis in one case; these were also detected with
PHF-1 in an adjacent section (Figure 2 and Supplemental
Table S4). Only rarely in FTDP-17 did AC-K280 immu-
noreactivity appear slightly more prominent than PHF-1
(Supplemental Table S4). PiD cases were largely negative
for AC-K280; however, a subset of regions in each PiD case
contained a varying degree of AC-K280 immunoreactivity
(Table 1). In most instances when AC-K280 immunoreac-
tivity was present, it was found in rare (one to ﬁve per slide)
glial inclusions or Pick bodies, although one case had three
regions with an abundance of AC-K280 lesions. The fourth
case had only rare AC-K280 tau pathological characteristics
in the entorhinal cortex of the hippocampus.Figure 1 Regional distribution and severity of AC-K280epositive tau path
K280epositive tau pathological characteristics based on median semiquantitative
map of median severity score ranging from no pathological characteristics (0, w
regions evaluated include the following: 1, midfrontal cortex gray matter; 2, oribi
gray matter; 5, superior/midtemporal cortex gray matter; 6, angular cortex gray m
9, midbrain; 10, pons; 11, medulla; 12, cervical spinal cord; 13, cerebellar cortex
substantia nigra; 18, midfrontal cortex white matter; 19, superior/midtemporal c
anterior cingulate gyrus white matter; 24, motor cortex white matter; 25, sensor
entorhinal cortex gray matter; 29, hippocampal formation (cornu ammonis 1 to 4
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Argyrophilic Grain Disease
AC-K280 was robust in tau-positive comma-shaped grains in
all ﬁve AGD cases studied herein (Figure 2), which were
largely restricted to limbic areas (one stage II and four stage
III). PHF-1epositive intracellular pretangles and neuroﬁbril-
lary tangles (NFTs), in addition to lightly tau-reactive swollen
achromatic ballooned neurons and coiled bodies in adjacent
white matter, were also labeled by AC-K280 (Figure 2). AC-
K280 was found in predominantly ThS-positive NFTs and
variably ThS-positive grains (Figure 3). Comparison with
isoform-speciﬁc tau mAbs conﬁrmed the predominance of 4R
tau in grains, because the 4R-speciﬁc tau mAb (RD4) dis-
played a similar predominance of intracellular NFTs and
grains toAC-K280,whereas a 3R-speciﬁcmAb (RD3)mainly
labeled AD-associated extracellular ghost tangles and diffuse
neuropil threads (NTs) that were not well labeled by the
AC-K280 antibody (Supplemental Figure S2). AC-K280
colocalized well with RD4 in grains that were largely RD3
negative, and colocalized with both isoform-speciﬁc mAbs in
intracellular NFTs (Supplemental Figure S2).
Tangle-Predominant Senile Dementia
TPSD cases had a predominance of PHF-1ereactive NFTs
similar to AD in the absence of signiﬁcant amyloid b deposits
(Supplemental Table S1). AC-K280 was a prominent feature
of intracellular NFTs and less conspicuous in extracellularological characteristics in patients with AGD or TPSD. Heat map of AC-
score for AGD (nZ 5) (A) and TPSD (n Z 5) (B). Bar graph depicts color
hite) to strong reactivity (3, red). Gray regions were not evaluated. Brain
tofrontal cortex gray matter; 3, motor cortex gray matter; 4, sensory cortex
atter; 7, visual cortex gray matter; 8, anterior cingulate cortex gray matter;
; 14, cerebellar white matter; 15, dentate nucleus; 16, hypothalamus; 17,
ortex white matter; 20, lentiform nucleus; 21, striatum; 22, amygdala; 23,
y cortex white matter; 26, angular cortex white matter; 27, thalamus; 28,
/subiculum); and 30, entorhinal cortex white matter.
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280ereactive NFTs in CA-1 were ThS positive (Figure 3). A
subset of cases had more widespread tau pathological char-
acteristics outside of the medial temporal lobe structuresThe American Journal of Pathology - ajp.amjpathol.org(Braak V to VI, n Z 2). These cases had abundant tau-
positive tangles and threads in the medial and lateral
temporal lobe cortical regions, with occasional tau-positive
glial inclusions largely restricted to gray matter, with some
compact lesions reminiscent of tufted astrocytes in PSP and
other, more diffuse, lesions resembling astrocytic plaques of
CBD. However, the lack of signiﬁcant white matter tau
pathological characteristics and infrequent tau inclusions in
the brainstem precluded these diagnoses and, thus, these
ﬁndings were most consistent with a diagnosis of TPSD. AC-
K280 immunoreactivity appeared similar in these cases, with
prominent deposition in neuronal tangles and glial lesions,
with minimal positivity in NTs or extracellular ghost tangles.
Familial AD
Both the PSEN1 p.G206A and p.S170P FAD cases displayed
typical AD tau pathological features, with widespread NTs,
NFTs, and neuritic plaques throughout cortical and, to
a lesser degree, subcortical structures (Supplemental Table
S4). Similar to sporadic AD,5 AC-K280 stained all forms
of neuroﬁbrillary pathological features but was most prom-
inent in ThS-positive intracellular NFTs and large dystrophic
neurites associated with neuritic plaques and was less reac-
tive to other NTs and extracellular NFTs (Figures 2 and 3).
Frontotemporal Dementia with Parkinsonism Linked to
Chromosome-17
FTDP-17 cases had microscopic ﬁndings consistent with
previous reports of abundant and widespread tau pathological
characteristics, albeit in different distributions in cases that
resembled PSP or CBD versus other phenotypic manifes-
tations of MAPT gene mutations.21,22 The p.P301L case
showed widespread strong immunoreactivity in tau deposits
throughout cortical and subcortical gray matter and, to a lesser
extent, white matter (Supplemental Table S4). Pleomorphic
neuronal tangles were prominent in superﬁcial and deep
cortical layers and were robustly reactive with AC-K280,
whereas associated diffuse threads seen with PHF-1 were
less evident in AC-K280estained sections (Figure 2). Pick-
like bodies were rarely observed with either epitope. GlialFigure 2 Acetylated and hyperphosphorylated tau pathological char-
acteristics in sporadic and hereditary tauopathies. AeP: Representative
images of AC-K280 staining and B-R display PHF-1 staining. Sections from
the amygdala in AGD show prominent AC-K280ereactive grains (arrow-
heads; A and C) and neuroﬁbrillary tangles (NFTs; asterisk; A) and ballooned
neurons (asterisk; C) similar to PHF-1 (B and D). AC-K280 reactivity in the
cornu ammonis (CA-1) region of the hippocampus in TPSD is seen mostly in
intracellular tangles (arrow; E), with less prominent staining of threads and
extracellular ghost tangles labeled by PHF-1 (F). CA-1 region of the hippo-
campus of a PSEN1 case (p.S170P) displays typical AD pathological charac-
teristics, with AC-K280 mainly in tangles (asterisk) and neuritic plaques
(arrow; G) and less prominent in diffuse threads than PHF-1 (H). Superior
temporal cortex (STC) of FTDP-17 cases (p.P301L and IVS10 þ 16) have
ACK280-reactive neuronal inclusions (I and M) and less prominent threads
than PHF-1 (J and N) in gray matter (GM) and a similar burden of glial tau
pathological features in white matter (WM; arrow; K and L). Non-
neurodegnerative disease control superior temporal cortex showing an
absence of AC-K280 (Q) and PHF-1 reactivity (R). Scale barZ 100 mm (R).
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Table 1 Summary of AC-K280 Reactivity in PiD Cases
Region
Case no.
1 2 3 4
Motor DDD Rare 0 NA
Striatum 0 0 þþ 0
Lentiform 0 0 Rare 0
Thalamus 0 0 Rare NA
Hypothalamus Rare D NA NA
Midbrain 0 0 0 0
Substantia nigra 0 0 Rare 0
Pons 0 0 0 0
Locus coeruleus 0 0 Rare 0
Cerebellar cortex 0 0 0 0
Dentate nucleus or cerebellum 0 0 0 0
Medulla 0 0 0 0
Cervical spinal cord 0 0 0 0
Midfrontal cortex Rare Rare þ 0
Orbital frontal cortex 0 Rare 0 0
Anterior cingulate cortex DDD 0 þ 0
Sensory cortex Rare 0 NA 0
Temporal cortex DDD 0 0 0
Angular cortex Rare 0 0 0
Visual cortex 0 0 NA 0
Entorhinal cortex or hippocampus Rare Rare 0 Rare
Cornu ammonis or hippocampus 0 0 0 0
Dentate gyrus or hippocampus 0 0 0 0
Amygdala Rare D 0 0
þ, weak; þþ, moderate ; þþþ, strong.
NA, tissue not available.
Figure 3 Colocalization of acetylated tau with ﬁbrillar (ThS þ) and
nonﬁbrillar (ThS ) tau inclusions. A: AGD entorhinal cortex (ERC) shows
AC-K280ereactive grains that are largely ThS negative (asterisks) and a ThS-
positive AD-associated tangle (arrow). B: Cornu ammonis region (CA-1) of
TPSDshowingmostlyAC-K280 in ThS-positive intracellular tangles (arrows) and
a subset of ThS-negative pretangles (asterisks). C: CA-1 region of FAD (S170P)
showing AC-K280ereactive tangle (arrows) and large dystrophic neurites
(asterisks) associated with a neuritic plaque. Tau lesions robustly positive for
AC-K280 in the temporal cortex of p.P301L (D) and IVS10 þ 16 FTDP-17 (E)
cases were minimally reactive to ThS (asterisks). Scale barZ 100 mm (E).
Irwin et alpathological features were moderate and mainly found in
coiled bodies and astrocytic lesions in white matter, both of
which were reactive to AC-K280 (Figure 2). In contrast, the
IVS10 þ 16 case had less prominent neuronal tau inclusions
and threads in graymatter and, instead, strong immunostaining
in white matter glial pathological features throughout the
neocortex and limbic cortices (Figure 2). Glial pathological
features were robustly positive for AC-K280 and, in rare
instances, slightly more prominent than PHF-1 (Supplemental
Table S4). AC-K280ereactive pathological characteristics in
FTDP-17 cases were largely negative for ThS (Figure 3). In
summary, AC-K280 was a prominent feature of the varied
glial and neuronal inclusions and less common in diffuse
threads seen in these FTDP-17 cases.
Pick Disease
Although PHF-1 and RD3 staining revealed numerous tau-
positive inclusions and diffusely distributed NTs, only
a minimal subset of tau lesions in the PiD cases was AC-K280
immunoreactive, and these included Pick bodies and compact
astrocytic inclusions (Supplemental Figure S3). Areas with
strong AC-K280 immunostaining in neuronal Pick body and
glial inclusions were conﬁrmed to contain 4R tau through
comparison of serial sections and double labeling with RD4.
The morphological characteristics of the AC-K280epositive
inclusions were similar to the RD4-stained inclusions and
both colocalized in neuronal and glial lesions, whereas double348labeling with RD3 demonstrated that some RD3-labeled
inclusions colocalized in the AC-K280epositive tau patho-
logical characteristics, but most often RD3 positivity did not
colocalize in AC-K280 (Supplemental Figure S3). PiD
inclusions, including those reactive to AC-K280, wereweakly
reactive for ThS (Supplemental Figure S3).
Discussion
We extend our previous studies of acetylated tau patho-
logical characteristics by documenting the presence of AC-
K280 immunoreactivity in the hallmark tau lesions of AGD,
TPSD, FAD, and FTDP-17 in a similar pattern and severity
to a well-annotated phosphorylated-epitope (Ser396/404).
Furthermore, we have also demonstrated the disease-speciﬁc
nature of the AC-K280 modiﬁcation because little or no AC-
K280 reactivity was found in the control cases examined
herein (Supplemental Table S4) or in previous studies.3,5
AC-K280 also detected tau pathological characteristics in
PiD, although to a much lesser extent and more variable
degree, reﬂecting the low burden of 4R tau inclusions in most
PiD cases. PiD is considered to be a 3R tauopathy, although
some cases have been found to have a variable, butajp.amjpathol.org - The American Journal of Pathology
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species of pathological tau.6e8 Indeed, we found minimal
AC-K280 immunoreactvity in PiD, which corresponded to
4R-containing lesions within individual cases. Interestingly,
AC-K280 was found in both 3R-positive and 3R-negative tau
inclusions, which probably reﬂects the presence of low levels
of 4R tau in some of these inclusions. These results highlight
the heterogeneity of pathological features within and
between individuals with PiD and further implicate the AC-
K280 modiﬁcation in pathological tau aggregations of
multiple etiologies.
AGD is a sporadic tauopathy associated with advanced
aging23,24 and cognitive impairment,25,26 bywhich tau-positive
grains have been localized to apical and basal dendrites27 and
contain a predominance of 4R tau.28e30 Indeed, we found
robust reactivity for AC-K280 in grain pathological features of
all ﬁve AGD brains examined herein, which exclusively
colocalized with another 4R-speciﬁc epitope detected by the
RD4 mAb. We found AC-K280 reactivity in AD-associated
intracellular tangles as well, and the common association of
AD pathological characteristics and AGD suggests that
formation of neuroﬁbrillary and grain pathological character-
istics may be mechanistically linked.26 Indeed, grains contain
manyof the samephosphorylation epitopes asADNFTs,31 and
herein we ﬁnd that AGD grain pathological features and AD-
like NFTs share the AC-K280 modiﬁcation as well. The
explanation for the discrepancy between robust AC-K280 in
grains and weak NT staining is not clear, but this may reﬂect
differences in deacetylase activity within the cytosolic
compartments of neurons, or differing mechanisms of inclu-
sion formation in grains versus NTs.
These ﬁndings are in contrast to a recent report by
Grinberg et al,32 who found a conspicuous absence of AC-
tau in grain pathological features in AGD, despite reactivity
in AD-type NFTs in these cases, using a novel monoclonal
antibody speciﬁc for acetylation of tau at the nearby lysine
residue 274 (AC-K274).32 One possibility for this discrep-
ancy is the effect of ﬁxatives used for tissue preparation,
because other tau antibodies for epitopes in the MTBD label
varying morphological characteristics of tau inclusions,
depending on tissue ﬁxation.33 Indeed, we have found AC-
K280 to be sensitive to formalin ﬁxation, requiring the use
of tissue ﬁxed in 70% ethanol with 150 mmol/L NaCl for
visualization of pathological characteristics in our studies (DJ
Irwin, TJ Cohen, VMY Lee, JQ Trojanowski, unpublished
observations). Notably, the study of Grinberg et al32 did test
the temporal effects of formalin ﬁxation on AC-K274 and
found that the formalin ﬁxation longer than 72 hours resulted
in decreased signal, but they did not examine other ﬁxatives.
Thus, these two epitopes could be differentially exposed in
grain pathological characteristics when AGD tissues are ﬁxed
in formalin versus ethanol. Another possibility for these
discrepancies is that AC-K274 is located in the ﬁrst MTBD,
which is present in both 3R and 4R tau isoforms, whereas AC-
K280 is found exclusively in 4R tau because of its presence in
the second MTBD; thus, the difference in speciﬁc AC tauThe American Journal of Pathology - ajp.amjpathol.orgepitopes detected by these antibodies could be responsible for
these observations as well.
Notably, we recently demonstrated that tau possesses a
novel enzymatic activity as a acetyltransferase with an
amino acid sequence and functional similarities to members
of the MYST family of enzymes.34 In this study, we
proposed that tau acetylates itself (autoacetylation) as part of
an autoinhibitory signaling mechanism to prevent tau-MT
interactions, and we also demonstrated that tau phosphory-
lation within the repeat regions could enhance tau autoa-
cetylation at K280.34 Future studies examining the effect of
different phospho-tau epitopes on tau acetylation are needed
to elucidate the biochemical interplay between these modi-
ﬁcations and the complex combinatorial set of modiﬁcations
that affect normal tau functions and contribute to the path-
ogenesis of tau pathological characteristics. Finally, we
speculate that the detection of diverse disease-speciﬁc tau
modiﬁcations in cerebral spinal ﬂuid of patients could aid in
the antemortem diagnosis of tauopathies.
TPSD is associated with advanced aging and shows
a distribution of neuroﬁbrillary tau pathological character-
istics that are similar to AD, and these pathological char-
acteristics contain both 3R and 4R tau isoforms.35,36 Indeed,
AC-K280 was highly associated with, but not exclusive to,
ThS-positive intracellular NFTs in TPSD and FAD and, less
commonly, in NTs and extracellular ghost tangles similar to
AD. In contrast, AC-K280 was also prominent in ThS-
negative neuronal pretangles and glial inclusions of
FTDP-17 (Figure 3). Notably, the MAPT p.P301L muta-
tion is thought to enhance 4R aggregation,37 whereas the
IVS10 þ 16 mutation is thought to increase splicing to
generate more 4R tau isoforms.1
These results are similar to observations of relative
minimal AC-K274 reactivity in diffuse NTs in AD and
prominence of AC-274 in two cases of PSP and CBD and
one case of FTDP-1732; they also agree with our previous
observations of AC-K280 in sporadic AD and the non-
amyloid lesions seen in the 4R tauopathies, CBD and PSP.5
In light of the ﬁndings shown in this study, together with
our recent observations of tau autoacetylation,34 it is plau-
sible to infer that prominent K280-positive immunoreac-
tivity detected in neuronal and glial tau aggregates results
from abnormal tau enzymatic activity, leading to the accu-
mulation of autoacetylated tau proteins that no longer efﬁ-
ciently bind MTs. Whether aberrant tau autoacetylation is
triggered by tau phosphorylation within MTBD regions
remains to be determined. Indeed, we speculate that autoa-
cetylation likely drives the formation of predominantly
thioﬂavin-positive tau inclusions, explaining the striking
correlation between K280 immunoreactivity and tau
amyloid deposits in AD.5 However, given that we observed
K280-positive inclusions that were not thioﬂavin positive in
CBD, PSP,5 and FTDP-17, K280 acetylation also can occur
independent from the formation of tau amyloid. Further
studies in animal and cell models are needed to clarify the
role of AC-K280 and tau autoacetylation in tangle349
Irwin et alformation, including possible interplay with phospho-, neo-,
and other acetyl-epitopes of tau, based on these morpho-
logical observations. Nevertheless, AC-K280 represents
a signiﬁcant marker of tau deposition in these diverse 4R-
containing tauopathies resulting from multiple pathogenic
mechanisms, including intrinsic mutations in MAPT, muta-
tions in Ab-associated PSEN1, and age-associated neuro-
degenerative conditions, thereby demonstrating the
importance of this AC-K280 modiﬁcation of tau in disease
pathogenesis.Acknowledgments
We thank the patients and their families. If not for their
meaningful contribution, this work would not be possible.
We also thank Young Baek, Curtis Tsai, Frank Smith, and
Jonathan Bekisz for their technical assistance and Dr. Peter
Davies for his generous contribution of the PHF-1 mAb.Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.04.025.References
1. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H,
et al: Association of missense and 50-splice-site mutations in tau with
the inherited dementia FTDP-17. Nature 1998, 393:702e705
2. Lee VM, Goedert M, Trojanowski JQ: Neurodegenerative tauopathies.
Annu Rev Neurosci 2001, 24:1121e1159
3. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP,
Trojanowski JQ, Lee VM: The acetylation of tau inhibits its function
and promotes pathological tau aggregation. Nat Commun 2011, 2:252
4. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW,
Huang EJ, Shen Y, Masliah E, Mukherjee C, Meyers D, Cole PA,
Ott M, Gan L: Acetylation of tau inhibits its degradation and
contributes to tauopathy. Neuron 2010, 67:953e966
5. Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM,
Trojanowski JQ: Acetylated tau, a novel pathological signature in
Alzheimer’s disease and other tauopathies. Brain 2012, 135:807e818
6. Zhukareva V, Mann D, Pickering-Brown S, Uryu K, Shuck T, Shah K,
Grossman M, Miller BL, Hulette CM, Feinstein SC, Trojanowski JQ,
Lee VM: Sporadic Pick’s disease: a tauopathy characterized by
a spectrum of pathological tau isoforms in gray and white matter. Ann
Neurol 2002, 51:730e739
7. Arai T, Ikeda K, Akiyama H, Shikamoto Y, Tsuchiya K, Yagishita S,
Beach T, Rogers J, Schwab C, McGeer PL: Distinct isoforms of tau
aggregated in neurons and glial cells in brains of patients with Pick’s
disease, corticobasal degeneration and progressive supranuclear palsy.
Acta Neuropathol 2001, 101:167e173
8. Yoshida M: Cellular tau pathology and immunohistochemical study of
tau isoforms in sporadic tauopathies. Neuropathology 2006, 26:
457e470
9. Xie SX, Baek Y, Grossman M, Arnold SE, Karlawish J, Siderowf A,
Hurtig H, Elman L, McCluskey L, Van Deerlin V, Lee VM,
Trojanowski JQ: Building an integrated neurodegenerative disease
database at an academic health center. Alzheimers Dement 2011, 7:
e84ee9335010. Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB,
Chatterjee A, Hurtig HI, Karlawish JH, Rosen HJ, Van Deerlin V,
Lee VM, Miller BL, Trojanowski JQ, Grossman M: Frontotemporal
dementia: clinicopathological correlations. Ann Neurol 2006, 59:
952e962
11. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J,
Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W,
Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A,
Spina S, Dickson DW, Trojanowski JQ, Mann DM: Nomenclature and
nosology for neuropathologic subtypes of frontotemporal lobar
degeneration: an update. Acta Neuropathol 2010, 119:1e4
12. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ,
Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS,
Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV,
Hyman BT: National Institute on Aging-Alzheimer’s Association
guidelines for the neuropathologic assessment of Alzheimer’s disease:
a practical approach. Acta Neuropathol 2012, 123:1e11
13. Braak H, Braak E: Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol 1991, 82:239e259
14. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM,
Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD), part II: stan-
dardization of the neuropathologic assessment of Alzheimer’s disease.
Neurology 1991, 41:479e486
15. Ferrer I, Santpere G, van Leeuwen FW: Argyrophilic grain disease.
Brain 2008, 131:1416e1432
16. Arnold SE, Vega IE, Karlawish JH, Wolk DA, Nunez J, Negron M,
Xie SX, Wang LS, Dubroff JG, McCarty-Wood E, Trojanowski JQ,
Van Deerlin V: Frequency and clinicopathological characteristics of
presenilin 1 Gly206Ala mutation in Puerto Rican Hispanics with
dementia. J Alzheimers Dis 2013, 33:1089e1095
17. Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis R,
Lendon CL, Goate AM, McKeel DW Jr, Morris JC: Novel presenilin 1
mutation (S170F) causing Alzheimer disease with Lewy bodies in the
third decade of life. Arch Neurol 2005, 62:1821e1830
18. Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM:
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at
serine residues 396 and 404. J Neurosci Res 1994, 39:669e673
19. de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A,
Bandopadhyay R, Utton M, Strand C, Jowett T, Khan N, Anderton B,
Wood N, Holton J, Revesz T, Lees A: Pathological inclusion bodies in
tauopathies contain distinct complements of tau with three or four
microtubule-binding repeat domains as demonstrated by new speciﬁc
monoclonal antibodies. Neuropathol Appl Neurobiol 2003, 29:
288e302
20. Van Deerlin VM, Gill LH, Farmer JM, Trojanowski JQ, Lee VM:
Familial frontotemporal dementia: from gene discovery to clinical
molecular diagnostics. Clin Chem 2003, 49:1717e1725
21. Lantos PL, Cairns NJ, Khan MN, King A, Revesz T, Janssen JC,
Morris H, Rossor MN: Neuropathologic variation in frontotemporal
dementia due to the intronic tau 10(þ16) mutation. Neurology 2002,
58:1169e1175
22. Nasreddine ZS, Loginov M, Clark LN, Lamarche J, Miller BL,
Lamontagne A, Zhukareva V, Lee VM, Wilhelmsen KC,
Geschwind DH: From genotype to phenotype: a clinical pathological,
and biochemical investigation of frontotemporal dementia and
parkinsonism (FTDP-17) caused by the P301L tau mutation. Ann
Neurol 1999, 45:704e715
23. Pham CT, de Silva R, Haik S, Verny M, Sachet A, Forette B, Lees A,
Hauw JJ, Duyckaerts C: Tau-positive grains are constant in centenar-
ians’ hippocampus. Neurobiol Aging 2011, 32:1296e1303
24. Ding ZT, Wang Y, Jiang YP, Yoshida M, Mimuro M, Inagaki T,
Iwase T, Hashizume Y: Argyrophilic grain disease: frequency and
neuropathology in centenarians. Acta Neuropathol 2006, 111:320e328
25. Jicha GA, Petersen RC, Knopman DS, Boeve BF, Smith GE,
Geda YE, Johnson KA, Cha R, Delucia MW, Braak H, Dickson DW,
Parisi JE: Argyrophilic grain disease in demented subjects presentingajp.amjpathol.org - The American Journal of Pathology
Acetylated Tau in Tauopathiesinitially with amnestic mild cognitive impairment. J Neuropathol Exp
Neurol 2006, 65:602e609
26. Thal DR, Schultz C, Botez G, Del Tredici K, Mrak RE, Grifﬁn WS,
Wiestler OD, Braak H, Ghebremedhin E: The impact of argyrophilic
grain disease on the development of dementia and its relationship to
concurrent Alzheimer’s disease-related pathology. Neuropathol Appl
Neurobiol 2005, 31:270e279
27. Ikeda K, Akiyama H, Kondo H, Haga C: A study of dementia with
argyrophilic grains: possible cytoskeletal abnormality in dendrospinal
portion of neurons and oligodendroglia. Acta Neuropathol 1995, 89:
409e414
28. Zhukareva V, Shah K, Uryu K, Braak H, Del Tredici K,
Sundarraj S, Clark C, Trojanowski JQ, Lee VM: Biochemical
analysis of tau proteins in argyrophilic grain disease, Alzheimer’s
disease, and Pick’s disease: a comparative study. Am J Pathol 2002,
161:1135e1141
29. Togo T, Sahara N, Yen SH, Cookson N, Ishizawa T, Hutton M, de
Silva R, Lees A, Dickson DW: Argyrophilic grain disease is a sporadic
4-repeat tauopathy. J Neuropathol Exp Neurol 2002, 61:547e556
30. Fujino Y, Wang DS, Thomas N, Espinoza M, Davies P, Dickson DW:
Increased frequency of argyrophilic grain disease in Alzheimer disease
with 4R tau-speciﬁc immunohistochemistry. J Neuropathol Exp Neurol
2005, 64:209e214The American Journal of Pathology - ajp.amjpathol.org31. Tolnay M, Spillantini MG, Goedert M, Ulrich J, Langui D, Probst A:
Argyrophilic grain disease: widespread hyperphosphorylation of tau
protein in limbic neurons. Acta Neuropathol 1997, 93:477e484
32. Grinberg LT, Wang X, Wang C, Sohn PD, Theoﬁlas P, Sidhu M,
Arevalo JB, Heinsen H, Huang EJ, Rosen H, Miller BL, Gan L,
Seeley WW: Argyrophilic grain disease differs from other tauopathies
by lacking tau acetylation. Acta Neuropathol 2013, 125:581e593
33. Bondareff W, Wischik CM, Novak M, Amos WB, Klug A, Roth M:
Molecular analysis of neuroﬁbrillary degeneration in Alzheimer’s
disease: an immunohistochemical study. Am J Pathol 1990, 137:
711e723
34. Cohen TJ, Friedmann D, Hwang AW, Marmorstein R, Lee VM: The
microtubule-associated tau protein has intrinsic acetyltransferase
activity. Nat Struct Mol Biol 2013, 20:756e762
35. Jellinger KA, Bancher C: Senile dementia with tangles (tangle
predominant form of senile dementia). Brain Pathol 1998, 8:367e376
36. Jellinger KA, Attems J: Neuroﬁbrillary tangle-predominant dementia:
comparison with classical Alzheimer disease. Acta Neuropathol 2007,
113:107e117
37. von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM,
Mandelkow E: Mutations of tau protein in frontotemporal dementia
promote aggregation of paired helical ﬁlaments by enhancing local
beta-structure. J Biol Chem 2001, 276:48165e48174351
